Trial Profile
Special Drug Use Investigation of Xarelto for VTE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jun 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms JPMS-XAR-VTE
- Sponsors Bayer
- 02 Jun 2021 Status changed from active, no longer recruiting to completed.
- 19 Apr 2021 Planned End Date changed from 31 Mar 2021 to 30 May 2021.
- 19 Jun 2020 Status changed from recruiting to active, no longer recruiting.